Pharmacodynamic_JJ Assessment_NP of_IN Ertapenem_NP (_( MK-0826_NP )_) against_IN Streptococcuspneumoniae_NP in_IN a_DT Murine_NP Neutropenic_NP Thigh_NP Infection_NP Model_NP The_DT objective_NN of_IN this_DT study_NN was_VBD to_TO determine_VB the_DT susceptibility_NN breakpoint_NN of_IN a_DT new_JJ carbapenem_NN ,_, ertapenem_NP (_( MK-0826_NP )_) ,_, against_IN Streptococcus_NP pneumoniae_NNS strains_NNS based_VBN on_IN bacterial_JJ density_NN and_CC survival_NN studies_NNS in_IN a_DT murine_JJ thigh_NN infection_NN model_NN ._SENT Sixteen_CD S._NP pneumoniae_NNS isolates_VBZ for_IN which_WDT MICs_NP ranged_VBD from_IN 0.015_CD to_TO 4.0_CD mg/liter_NN were_VBD tested_VBN with_IN neutropenic_JJ ICR_NP mice_NNS ._SENT Animals_NNS were_VBD infected_VBN with_IN bacteria_NNS at_IN 105_CD to_TO 106_CD CFU_NN per_IN thigh_NN and_CC were_VBD treated_VBN with_IN ertapenem_NN starting_VBG at_IN 2_CD h_NN postinfection_NN for_IN 4_CD days_NNS ._SENT Ertapenem_NP was_VBD given_VBN subcutaneously_RB at_IN 50_CD mg/kg_NN of_IN body_NN weight_NN every_DT 6_CD h_NN ,_, which_WDT simulates_VBZ the_DT human_JJ pharmacodynamic_JJ profile_NN (_( in_IN particular_JJ ,_, the_DT duration_NN of_IN time_NN that_IN the_DT concentration_NN of_IN free_JJ drug_NN remains_VBZ above_IN the_DT MIC_NN of_IN 2_CD mg/liter_NN )_) ._SENT At_IN 0_CD and_CC 24_CD h_NN postinfection_NN ,_, thighs_NNS were_VBD harvested_VBN for_IN bacterial_JJ density_NN determination_NN ._SENT Survival_NN was_VBD assessed_VBN during_IN 4_CD days_NNS of_IN therapy_NN and_CC 3_CD days_NNS after_IN the_DT therapy_NN ._SENT A_DT protein_NN binding_VBG study_NN was_VBD conducted_VBN with_IN mice_NNS by_IN use_NN of_IN the_DT ultrafiltration_NN method_NN ._SENT Protein_NN binding_NN in_IN mice_NNS was_VBD approximately_RB 95_CD %_NN ,_, which_WDT is_VBZ comparable_JJ to_TO that_DT in_IN humans_NNS ._SENT The_DT average_JJ change_NN in_IN bacterial_JJ density_NN ranged_VBN from_IN -0.22_CD to_TO -4.4_CD log_NN CFU_NP per_IN thigh_NN over_IN 24_CD h_NN compared_VBN to_TO 0-h_NN controls_NNS ._SENT The_DT extent_NN of_IN microbial_JJ eradication_NN was_VBD dependent_JJ on_IN the_DT MIC_NN for_IN the_DT S._NP pneumoniae_NNS isolate_VBP ._SENT Substantial_JJ bactericidal_JJ activities_NNS (_( i.e._FW ,_, killing_VBG of_IN approximately_RB 2_CD log_NN CFU_NP per_IN thigh_NN )_) were_VBD consistently_RB observed_VBN against_IN isolates_NNS for_IN which_WDT MICs_NP were_VBD <=2_JJ mg/liter_NN ,_, which_WDT also_RB resulted_VBD in_IN nearly_RB 100_CD %_NN survival_NN during_IN the_DT 4_CD days_NNS of_IN drug_NN dosing_VBG and_CC 3_CD days_NNS after_IN the_DT therapy_NN ._SENT Less-pronounced_JJ and_CC highly_RB variable_JJ bactericidal_JJ activities_NNS were_VBD detected_VBN against_IN isolates_NNS for_IN which_WDT the_DT MIC_NN was_VBD 4_CD mg/liter_NN ._SENT Substantial_JJ enhancement_NN in_IN bactericidal_JJ activity_NN was_VBD observed_VBN for_IN CBA/J_NP mice_NNS and_CC is_VBZ attributed_VBN to_TO the_DT contribution_NN of_IN the_DT host_NN defenses_NNS in_IN the_DT immunocompetent_JJ species_NN ._SENT Assessment_NN of_IN the_DT effectiveness_NN of_IN ertapenem_NN by_IN bacterial-density_NN reduction_NN over_IN 24_CD h_NN and_CC by_IN survival_NN over_IN 4_CD days_NNS of_IN therapy_NN in_IN the_DT murine_JJ thigh_NN infection_NN model_NN reveals_VBZ that_IN the_DT drug_NN maintains_VBZ maximal_JJ efficacy_NN against_IN S._NP pneumoniae_NNS isolates_VBZ for_IN which_WDT the_DT MIC_NN of_IN this_DT agent_NN is_VBZ <=2_JJ mg/liter_NN ._SENT Ertapenem_NP (_( MK-0826_NP )_) is_VBZ a_DT new_JJ ,_, long-acting_VBG 1-beta-methyl_JJ carbapenem_NN with_IN potent_JJ antimicrobial_JJ activity_NN against_IN a_DT variety_NN of_IN pathogenic_JJ species_NNS including_VBG pneumococci_NNS ._SENT While_IN this_DT agent_NN apparently_RB has_VBZ good_JJ in_IN vitro_NN activity_NN against_IN Streptococcus_NP pneumoniae_NNS ,_, the_DT pharmacodynamic_JJ assessment_NN of_IN the_DT susceptibility_NN breakpoint_NN of_IN ertapenem_NN against_IN this_DT important_JJ pathogen_NN has_VBZ not_RB been_VBN fully_RB described_VBN ._SENT The_DT availability_NN of_IN these_DT data_NNS will_MD assist_VB not_RB only_RB in_IN optimizing_VBG the_DT effectiveness_NN of_IN the_DT prescribed_JJ antimicrobial_JJ regimen_NN in_IN clinical_JJ practice_NN but_CC also_RB in_IN the_DT assessment_NN of_IN appropriate_JJ National_NP Committee_NP for_IN Clinical_NP Laboratory_NP Standards_NP (_( NCCLS_NP )_) breakpoints_NNS for_IN this_DT antimicrobial_JJ agent_NN ._SENT The_DT purpose_NN of_IN the_DT present_JJ study_NN was_VBD to_TO determine_VB the_DT susceptibility_NN breakpoint_NN of_IN ertapenem_NN against_IN S._NP pneumoniae_NNS strains_NNS based_VBN on_IN bacterial_JJ density_NN and_CC survival_NN studies_NNS using_VBG a_DT murine_JJ model_NN of_IN pneumococcal_JJ thigh_NN infection_NN ._SENT Antimicrobial_JJ agents_NNS ._SENT |_SYM Ertapenem_NP (_( analytical_JJ grade_NN standard_NN ;_: lot_NN L-749345-002C089_NP ,_, 98.4_CD %_NN purity_NN )_) for_IN in_IN vitro_NN and_CC in_IN vivo_JJ testing_NN was_VBD obtained_VBN from_IN Merck_NP Research_NP Laboratory_NP ._SENT Ertapenem_NP was_VBD reconstituted_VBN with_IN a_DT 0.1_CD M_NP morpholineethanesulfonic_JJ acid_NN (MES)-ethylene_NN glycol_NN (_( 1:1_CD ,_, vol/vol_NP )_) solution_NN for_IN all_DT in_IN vitro_NN testing_NN ._SENT For_IN animal_NN dosing_VBG ,_, an_DT ertapenem_NN solution_NN was_VBD freshly_RB prepared_VBN with_IN sterile_JJ water_NN for_IN injection_NN prior_RB to_TO drug_NN administration_NN ._SENT Bacterial_JJ isolates_NNS and_CC susceptibilities_NNS ._SENT |_SYM Sixteen_JJ clinical_JJ isolates_NNS of_IN S._NP pneumoniae_NNS were_VBD included_VBN in_IN this_DT study_NN ._SENT The_DT MIC_NN for_IN ertapenem_NN was_VBD determined_VBN by_IN the_DT microdilution_NN method_NN according_VBG to_TO NCCLS_NP guidelines_NNS by_IN using_VBG cation-adjusted_JJ Mueller-Hinton_NP broth_NN (_( 20_CD to_TO 25_CD mg_NN of_IN calcium/liter_NN and_CC 10_CD to_TO 12.5_CD mg_NN of_IN magnesium/liter_NN )_) with_IN 5_CD %_NN lysed_VBD horse_NN blood_NN in_IN ambient_JJ air_NN ._SENT Trypticase_NP soy_NN agar_NN with_IN 5_CD %_NN sheep_NN blood_NN was_VBD used_VBN as_IN the_DT growth_NN medium_NN for_IN S._NP pneumoniae_NP isolates_VBZ ._SENT Thigh_NN infection_NN model_NN ._SENT |_SYM Specific-pathogen-free_NP female_JJ ICR_NP mice_NNS weighing_VBG approximately_RB 25_CD g_NN (_( Harlan_NP Sprague_NP Dawley_NP Inc._NP ,_, Indianapolis_NP ,_, Ind._NP )_) were_VBD utilized_VBN throughout_IN the_DT experiment_NN ._SENT All_DT care_NN and_CC the_DT experiments_NNS described_VBN in_IN this_DT report_NN were_VBD approved_VBN by_IN and_CC performed_VBN in_IN accordance_NN with_IN guidelines_NNS of_IN the_DT Hartford_NP Hospital_NP Institutional_NP Animal_NP Care_NP and_CC Use_NP Committee_NP (_( IACUC_NP )_) ._SENT Mice_NNS were_VBD rendered_VBN transiently_RB neutropenic_JJ by_IN two_CD intraperitoneal_JJ (_( i.p._JJ )_) injections_NNS of_IN cyclophosphamide_NN ,_, the_DT first_JJ at_IN a_DT dose_NN of_IN 150_CD mg/kg_NN of_IN body_NN weight_NN 4_CD days_NNS before_IN infection_NN and_CC the_DT second_NN at_IN a_DT dose_NN of_IN 100_CD mg/kg_NN 1_CD day_NN before_IN infection_NN ._SENT Renal_JJ impairment_NN was_VBD induced_VBN by_IN a_DT single_JJ i.p._JJ injection_NN of_IN uranyl_NN nitrate_NN 3_CD days_NNS before_IN infection_NN ._SENT Broth_NN cultures_NNS of_IN the_DT test_NN organism_NN were_VBD grown_VBN overnight_RB and_CC subsequently_RB diluted_VBN to_TO an_DT inoculum_NN of_IN approximately_RB 106_CD to_TO 107_CD CFU/ml_NN ._SENT Final_JJ inoculum_NN concentrations_NNS were_VBD confirmed_VBN by_IN serial-dilution_NN and_CC plating_NN techniques_NNS ._SENT Thigh_NN infection_NN with_IN each_DT of_IN the_DT test_NN isolates_NNS was_VBD produced_VBN by_IN injecting_VBG 0.1_CD ml_NN of_IN the_DT inoculum_NN into_IN each_DT mouse_NN thigh_NN 2_CD h_NN prior_JJ to_TO initiation_NN of_IN antimicrobial_JJ therapy_NN ._SENT Pharmacokinetic_JJ studies_NNS and_CC dosing-regimen_NNS determination_NN ._SENT |_SYM Pharmacokinetic_NP studies_NNS were_VBD undertaken_VBN using_VBG neutropenic_JJ ICR_NP mice_NNS in_IN order_NN to_TO find_VB an_DT ertapenem_NN regimen_NN for_IN the_DT murine_JJ pneumococcal_JJ thigh_NN infection_NN model_NN that_WDT simulates_VBZ the_DT pharmacokinetic_JJ profile_NN observed_VBN in_IN humans_NNS receiving_VBG 1-g_NN dosing_VBG every_DT 24_CD h_NN (_( q24h_NN )_) ._SENT In_IN an_DT attempt_NN to_TO optimize_VB the_DT pharmacokinetic_JJ profile_NN of_IN ertapenem_NN ,_, renal_JJ impairment_NN was_VBD induced_VBN by_IN a_DT single_JJ i.p._JJ injection_NN of_IN uranyl_NN nitrate_NN (_( 5_CD mg/kg_NN )_) 3_CD days_NNS before_IN infection_NN ._SENT Single_JJ doses_NNS of_IN ertapenem_NN at_IN 20_CD ,_, 50_CD ,_, and_CC 100_CD mg/kg_NN were_VBD administered_VBN by_IN subcutaneous_JJ injection_NN in_IN a_DT 0.2-ml_NN volume_NN 2_CD h_NN after_IN pneumococcal_JJ thigh_NN inoculation_NN ._SENT Blood_NN samples_NNS from_IN four_CD mice_NNS per_IN time_NN point_NN were_VBD collected_VBN by_IN intracardiac_JJ puncture_NN at_IN 0.25_CD ,_, 0.5_CD ,_, 1_CD ,_, 2_CD ,_, 4_CD ,_, 6_CD ,_, and_CC 8_CD h_NN after_IN dosing_VBG ._SENT Serum_NP was_VBD separated_VBN by_IN centrifugation_NN at_IN 3,000_CD x_NN g_NN for_IN 10_CD min_NN and_CC was_VBD then_RB transferred_VBN into_IN polypropylene_NN tubes_NNS and_CC stored_VBN at_IN -80C_NN until_IN analysis_NN ._SENT Concentrations_NNS of_IN ertapenem_NN in_IN murine_JJ serum_NN were_VBD determined_VBN by_IN using_VBG a_DT validated_VBN reverse-phase_NN high-pressure_JJ liquid_JJ chromatography_NN (_( HPLC_NP )_) assay_NN ._SENT The_DT sample_NN extraction_NN method_NN involved_VBD liquid-phase_NN extraction_NN ._SENT After_IN addition_NN of_IN 50_CD mul_NN of_IN an_DT internal_JJ standard_NN (_( meropenem_NP ,_, 50_CD mg/liter_NN )_) to_TO the_DT mouse_NN serum_NN samples_NNS (_( 200_CD mul_NN )_) ,_, 800_CD mul_NN of_IN acetonitrile_NN was_VBD added_VBN ._SENT Protein_NN precipitation_NN was_VBD achieved_VBN by_IN a_DT brief_JJ vortexing_NN followed_VBN by_IN centrifugation_NN at_IN 2,600_CD x_NN g_NN for_IN 10_CD min_NN ._SENT Supernatants_NNS were_VBD transferred_VBN into_IN clean_JJ labeled_VBN tubes_NNS ,_, and_CC then_RB 2.5_CD ml_NN of_IN dichloromethane_NN was_VBD added_VBN ._SENT Again_RB samples_NNS were_VBD briefly_RB vortexed_VBN and_CC subjected_VBN to_TO centrifugation_NN ._SENT The_DT resultant_JJ aqueous_JJ solution_NN was_VBD separated_VBN and_CC transferred_VBN into_IN vials_NNS for_IN injection_NN into_IN the_DT HPLC_NP system_NN ._SENT Chromatography_NN was_VBD performed_VBN at_IN ambient_JJ temperature_NN on_IN a_DT reversed-phase_JJ C18_NP column_NN (_( 5_CD mum_NN ;_: 100_CD by_IN 4.6_CD mm_NN ;_: Keystone_NP Scientific_NP Inc._NP ,_, Belletonte_NP ,_, Pa._NP )_) with_IN an_DT injection_NN volume_NN of_IN 30_CD mul_NN ._SENT The_DT mobile_JJ phase_NN ,_, consisting_VBG of_IN 25_CD mM_NP phosphate_NN buffer_NN (_( pH_NN 6.5_CD )_) solution-methanol_NN (_( 100:9.5_CD ,_, vol/vol_NP )_) ,_, was_VBD delivered_VBN via_IN a_DT Waters_NP HPLC_NP pump_NN at_IN a_DT flow_NN rate_NN of_IN 1.0_CD ml/min_NN ._SENT Ertapenem_NP and_CC the_DT internal_JJ standard_NN were_VBD eluted_VBN at_IN approximately_RB 10.5_CD and_CC 14.9_CD min_NN ,_, respectively_RB ._SENT UV_NP detection_NN was_VBD performed_VBN at_IN a_DT wavelength_NN of_IN 300_CD nm_NN ._SENT The_DT assay_NN was_VBD linear_JJ over_IN a_DT range_NN of_IN 0.15_CD to_TO 50_CD mg/liter_NN ._SENT Intra-assay_NN coefficients_NNS of_IN variation_NN for_IN the_DT low_JJ (_( 1.0-mg/liter_NP )_) and_CC high_JJ (_( 40-mg/liter_JJ )_) check_NN samples_NNS were_VBD 2.2_CD and_CC 4.0_CD %_NN ,_, respectively_RB ._SENT Interassay_NN coefficients_NNS of_IN variation_NN for_IN the_DT low_JJ and_CC high_JJ check_NN samples_NNS were_VBD 3.6_CD and_CC 4.3_CD %_NN ,_, respectively_RB ._SENT Individual_JJ concentration_NN data_NNS from_IN all_PDT the_DT dosing_VBG regimens_NNS were_VBD analyzed_VBN by_IN using_VBG a_DT population_NN approach_NN with_IN the_DT NONMEM_NP computer_NN program_NN ,_, version_NN V_CD ,_, level_NN 1.1_CD ;_: NM-TRAN_NP ,_, version_NN III_NP ,_, level_NN 1.0_CD ;_: and_CC PREDPP_NP ,_, version_NN IV_NP ,_, level_NN 1.0_CD (_( NONMEM_NP Project_NP Group_NP ,_, University_NP of_IN California_NP at_IN San_NP Francisco_NP ,_, San_NP Francisco_NP ,_, Calif._NP )_) ._SENT One-_JJ and_CC two-compartment_JJ structural_JJ models_NNS with_IN first-order_NN absorption_NN and_CC elimination_NN were_VBD compared_VBN to_TO fit_VB the_DT data_NNS by_IN using_VBG the_DT first-order_NN estimation_NN method_NN ._SENT Residual_JJ error_NN was_VBD modeled_VBN by_IN using_VBG a_DT combined_JJ proportional_JJ and_CC additive_JJ error_NN model_NN ._SENT Model_NN selection_NN was_VBD based_VBN on_IN a_DT likelihood_NN ratio_NN test_NN ,_, Akaike_NP 's_POS information_NN criterion_NN ,_, and_CC evaluation_NN of_IN goodness-of-fit_NN plots_NNS from_IN the_DT model_NN ._SENT The_DT statistical_JJ significance_NN level_NN was_VBD set_VBN a_DT priori_NN at_IN 0.005_CD ._SENT Based_VBN on_IN the_DT population_NN parameter_NN estimates_NNS from_IN NONMEM_NP analysis_NN ,_, the_DT dosing_VBG regimen_NN was_VBD calculated_VBN in_IN such_PDT a_DT way_NN as_RB to_TO simulate_VB the_DT drug_NN exposure_NN found_VBN in_IN humans_NNS following_VBG 1-g_JJ q24h_NN dosing_VBG (_( area_NN under_IN the_DT concentration-time_JJ curve_NN from_IN 0_CD to_TO 24_CD h_NN [_SYM AUC0-24_NP ]_SYM ,_, 500_CD to_TO 600_CD mgh/liter_NN ;_: maximum_JJ concentration_NN of_IN drug_NN in_IN serum_NN [_SYM Cmax_NP ]_SYM ,_, 140_CD mg/liter_NN ;_: duration_NN of_IN time_NN that_IN the_DT free_JJ drug_NN concentration_NN remains_VBZ above_IN the_DT MIC_NN of_IN 2_CD mg/liter_NN [_SYM T>MICfree_NP ]_SYM ,_, 20_CD %_NN )_) ._SENT Protein_NN binding_NN ._SENT |_SYM The_DT protein_NN binding_VBG of_IN ertapenem_NN was_VBD determined_VBN by_IN an_DT ultrafiltration_NN (_( Centrifree_NP )_) method_NN with_IN ICR_NP mouse_NN specimens_NNS ._SENT Three_CD concentrations_NNS of_IN ertapenem_NN (_( 1_CD ,_, 10_CD ,_, and_CC 100_CD mg/liter_NN )_) were_VBD tested_VBN with_IN freshly_RB collected_VBN mouse_NN serum_NN ._SENT All_DT spiked_JJ serum_NN samples_NNS were_VBD placed_VBN in_IN a_DT 37C_JJ shaking_VBG water_NN bath_NN for_IN 10_CD min_NN before_IN being_VBG loaded_VBN onto_IN Centrifree_JJ filters_NNS (_( 30,000-molecular-weight_JJ cutoff_NN ;_: Millipore_NP )_) ._SENT Filtrates_NNS were_VBD separated_VBN by_IN centrifugation_NN at_IN 1,000_CD x_NN g_NN for_IN 15_CD min_NN ,_, and_CC samples_NNS were_VBD measured_VBN by_IN a_DT validated_VBN HPLC_NP method_NN ._SENT Therapeutic_JJ efficacy_NN as_IN assessed_VBN by_IN bacterial_JJ density_NN ._SENT |_SYM Starting_VBG at_IN 2_CD h_NN after_IN infection_NN ,_, ICR_NP mice_NNS were_VBD treated_VBN with_IN ertapenem_NN at_IN 50_CD mg/kg_NN q6h_NN by_IN subcutaneous_JJ injection_NN in_IN a_DT 0.2-ml_NN volume_NN for_IN 24_CD h._NN This_DT dosing_VBG regimen_NN was_VBD calculated_VBN on_IN the_DT basis_NN of_IN the_DT preliminary_JJ pharmacokinetic_JJ analysis_NN to_TO simulate_VB the_DT drug_NN exposure_NN observed_VBN in_IN humans_NNS ._SENT Control_NN animals_NNS received_VBD water_NN in_IN the_DT same_JJ volume_NN (_( 0.2_CD ml_NN )_) and_CC on_IN the_DT same_JJ schedule_NN as_IN ertapenem_NN ._SENT Untreated_JJ control_NN mice_NNS (_( four_CD per_IN group_NN )_) were_VBD sacrificed_VBN just_RB prior_RB to_TO antibiotic_JJ initiation_NN and_CC after_IN 24_CD h._JJ Ertapenem-treated_JJ animals_NNS were_VBD euthanized_JJ by_IN CO2_NP exposure_NN followed_VBN by_IN cervical_JJ dislocation_NN after_IN 24_CD h._NN After_IN sacrifice_NN ,_, both_DT thighs_NNS were_VBD removed_VBN and_CC individually_RB homogenized_VBN in_IN normal_JJ saline_NN ._SENT Serial_JJ dilutions_NNS were_VBD plated_VBN on_IN Trypticase_NP soy_NN agar_NN with_IN 5_CD %_NN sheep_NN blood_NN for_IN CFU_NP determinations_NNS ._SENT For_IN the_DT purposes_NNS of_IN these_DT studies_NNS ,_, efficacy_NN (_( change_NN in_IN bacterial_JJ density_NN )_) was_VBD calculated_VBN by_IN subtracting_VBG the_DT mean_JJ log_NN CFU_NP per_IN thigh_NN of_IN the_DT control_NN mice_NNS obtained_VBD just_RB prior_JJ to_TO antibiotic_JJ administration_NN from_IN the_DT log_NN CFU_NP per_IN thigh_NN of_IN each_DT ertapenem-treated_JJ mouse_NN at_IN the_DT end_NN of_IN therapy_NN (_( 24_CD h_NN )_) ._SENT In_IN addition_NN ,_, we_PP compared_VBD the_DT bactericidal_JJ activities_NNS of_IN ertapenem_NN against_IN S._NP pneumoniae_NNS in_IN the_DT murine_JJ neutropenic_JJ and_CC nonneutropenic_JJ thigh_NN infection_NN models_NNS ._SENT An_DT S._NP pneumoniae_NNS strain_NN (_( SP-129_NP ;_: MIC_NP ,_, 2_CD mg/liter_NN )_) was_VBD tested_VBN with_IN neutropenic_JJ ICR_NP mice_NNS and_CC immunocompetent_JJ CBA/J_NP mice_NNS (_( Charles_NP River_NP Laboratories_NPS ,_, Wilmington_NP ,_, Mass._NP )_) ._SENT The_DT animal_JJ infection_NN procedure_NN for_IN CBA/J_NP mice_NNS was_VBD the_DT same_JJ as_IN the_DT procedure_NN described_VBD above_IN for_IN ICR_NP mice_NNS except_VBP that_IN the_DT CBA/J_NP mice_NNS received_VBD no_DT cyclophosphamide_NN ._SENT Animals_NNS were_VBD inoculated_VBN at_IN 105_CD to_TO 106_CD CFU_NN per_IN thigh_NN and_CC were_VBD treated_VBN starting_VBG at_IN 2_CD h_NN postinfection_NN for_IN 24_CD h._NN At_IN 0_CD and_CC 24_CD h_NN postinfection_NN ,_, thighs_NNS were_VBD harvested_VBN for_IN bacterial_JJ density_NN determination_NN ._SENT The_DT regimens_NNS for_IN ertapenem_NN were_VBD 50_CD mg/kg_NN q6h_NN and_CC q24h_NN ._SENT Four_CD animals_NNS were_VBD used_VBN in_IN each_DT study_NN arm_NN ._SENT Therapeutic_JJ efficacy_NN as_IN assessed_VBN by_IN survival_NN ._SENT |_SYM Groups_NNS of_IN 20_CD mice_NNS were_VBD similarly_RB infected_VBN with_IN each_DT test_NN strain_NN for_IN evaluation_NN of_IN survival_NN after_IN 96_CD h_NN of_IN therapy_NN ._SENT Ertapenem_NN therapy_NN (_( 50_CD mg/kg_NN q6h_NN )_) was_VBD initiated_VBN 2_CD h_NN after_IN inoculation_NN in_IN 15_CD animals_NNS ._SENT The_DT remaining_VBG five_CD animals_NNS received_VBD the_DT same_JJ volume_NN of_IN water_NN q6h_NN and_CC served_VBN as_IN the_DT controls_NNS ._SENT Cumulative_JJ mortality_NN was_VBD calculated_VBN during_IN 96_CD h_NN of_IN therapy_NN ._SENT Although_IN death_NN has_VBZ historically_RB been_VBN used_VBN as_IN an_DT end_NN point_NN for_IN studies_NNS of_IN this_DT type_NN ,_, this_DT end_NN point_NN is_VBZ no_RB longer_RBR suitable_JJ in_IN the_DT present_JJ era_NN of_IN animal_JJ research_NN ._SENT Therefore_RB ,_, our_PP$ study_NN methodology_NN has_VBZ been_VBN modified_VBN to_TO contemporary_JJ standards_NNS ._SENT We_PP utilized_VBD the_DT following_VBG approach_NN in_IN order_NN to_TO lessen_VB the_DT duration_NN of_IN pain_NN and_CC suffering_NN during_IN the_DT mortality_NN experiment_NN ._SENT (_( i_NP )_) Animals_NPS were_VBD monitored_VBN four_CD times_NNS daily_JJ by_IN members_NNS of_IN the_DT study_NN team_NN who_WP have_VBP been_VBN trained_VBN and_CC are_VBP experienced_VBN in_IN recognizing_VBG the_DT signs_NNS of_IN illness_NN and_CC abnormal_JJ behavior_NN ._SENT (_( ii_NP )_) Animals_NNS which_WDT appeared_VBD to_TO have_VB substantial_JJ alterations_NNS in_IN posture_NN (_( e.g._FW ,_, abnormal_JJ posture_NN or_CC head_NN tucked_VBN into_IN abdomen_NN )_) ,_, coat_NN ,_, exudate_NN around_IN eyes_NNS and/or_CC nose_NN ,_, and_CC breathing_NN or_CC movement_NN were_VBD removed_VBN from_IN the_DT group_NN housing_NN and_CC were_VBD euthanized_JJ ._SENT The_DT term_NN "_`` mortality_NN "_'' has_VBZ been_VBN used_VBN as_IN an_DT end_NN point_NN for_IN this_DT study_NN ;_: however_RB ,_, it_PP should_MD be_VB clearly_RB understood_VBN that_IN ,_, when_WRB possible_JJ ,_, every_DT attempt_NN was_VBD made_VBN to_TO minimize_VB pain_NN and_CC suffering_NN and_CC that_IN the_DT animals_NNS were_VBD euthanized_JJ prior_RB to_TO naturally_RB succumbing_VBG to_TO infection_NN if_IN pain_NN and_CC suffering_NN were_VBD observed_VBN ._SENT For_IN the_DT purposes_NNS of_IN this_DT study_NN ,_, death_NN due_JJ to_TO the_DT natural_JJ infection_NN process_NN and_CC euthanasia_NN were_VBD considered_VBN the_DT same_JJ end_NN point_NN for_IN experimental_JJ and_CC statistical_JJ purposes_NNS ._SENT Data_NP analysis_NN ._SENT |_SYM Spearman_NP 's_POS rank_JJ correlation_NN coefficient_NN was_VBD used_VBN to_TO evaluate_VB the_DT correlation_NN between_IN change_NN in_IN CFU_NP and_CC T>MICfree_NP for_IN ertapenem_NN after_IN 24_CD h_NN of_IN therapy_NN as_RB well_RB as_IN the_DT correlation_NN between_IN mortality_NN and_CC T>MICfree_JJ for_IN ertapenem_NN after_IN 96_CD h_NN of_IN therapy_NN ._SENT In_IN addition_NN ,_, the_DT sigmoid_JJ Emax_NP model_NN was_VBD applied_VBN to_TO further_RBR evaluate_VB the_DT relationship_NN between_IN these_DT variables_NNS ._SENT The_DT MICs_NN of_IN ertapenem_NN for_IN the_DT S._NP pneumoniae_NN isolates_NNS incorporated_VBN into_IN this_DT study_NN are_VBP displayed_VBN in_IN Table_NP ._SENT The_DT test_NN organisms_NNS selected_VBN represent_VBP a_DT wide_JJ range_NN of_IN sensitivities_NNS to_TO ertapenem_NN ,_, with_IN MICs_NP ranging_VBG from_IN 0.015_CD to_TO 4_CD mg/liter_NN ._SENT Concentration-independent_JJ protein_NN binding_VBG levels_NNS for_IN ertapenem_NN were_VBD observed_VBN over_IN the_DT concentrations_NNS studied_VBD ._SENT The_DT average_JJ protein_NN binding_VBG level_NN in_IN murine_JJ serum_NN was_VBD 95.5_CD %_NN +-_NN 1.0_CD %_NN ,_, which_WDT is_VBZ comparable_JJ to_TO the_DT 94_CD %_NN protein_NN binding_VBG at_IN a_DT concentration_NN of_IN 100_CD mg/liter_NN observed_VBN in_IN humans_NNS (_( ;_: product_NN package_NN insert_NN ,_, 2001_CD ,_, Merck_NP &_CC Co._NP ,_, Inc._NP ,_, Whitehouse_NP Station_NP ,_, N.J._NP )_) ._SENT A_DT total_NN of_IN 130_CD concentrations_NNS were_VBD used_VBN to_TO compute_VB population_NN pharmacokinetic_JJ parameters_NNS ._SENT The_DT pharmacokinetic_JJ disposition_NN of_IN ertapenem_NN in_IN mice_NNS was_VBD best_RBS described_VBN with_IN a_DT one-compartment_NN model_NN with_IN first-order_NN absorption_NN and_CC elimination_NN ;_: parameter_NN estimates_NNS are_VBP presented_VBN in_IN Table_NP ._SENT The_DT population_NN analysis_NN was_VBD quite_RB robust_JJ ,_, as_RB evidenced_VBN by_IN the_DT plot_NN of_IN the_DT observed_VBN versus_IN the_DT population_NN predicted_VBD concentrations_NNS of_IN ertapenem_NN in_IN infected_JJ animals_NNS ._SENT Based_VBN on_IN the_DT population_NN analysis_NN ,_, a_DT 50-mg/kg_JJ q6h_NN dosing_VBG regimen_NN produced_VBD an_DT AUC0-24_NP of_IN 586_CD mg_NN h/liter_NN ,_, a_DT Cmax_NP of_IN 140_CD mg/liter_NN ,_, and_CC a_DT T>_NP MICfree_NP of_IN 22_CD %_NN ,_, which_WDT are_VBP comparable_JJ to_TO those_DT found_VBN in_IN humans_NNS after_IN 1-g_JJ q24h_NN dosing_VBG ._SENT This_DT simulated_JJ regimen_NN was_VBD then_RB administered_VBN to_TO another_DT group_NN of_IN mice_NNS to_TO confirm_VB the_DT predicted_VBN values_NNS of_IN the_DT modeling_NN scheme_NN ._SENT As_IN displayed_VBN in_IN Fig._NN ,_, the_DT regimen_NN selected_VBN produced_VBD a_DT concentration-versus-time_JJ profile_NN in_IN this_DT murine_JJ model_NN that_WDT was_VBD comparable_JJ to_TO the_DT NONMEM-predicted_JJ profile_NN ._SENT As_IN presented_VBN in_IN Fig._NN ,_, excellent_JJ recovery_NN of_IN bacteria_NNS from_IN infected_JJ thighs_NNS of_IN control_NN animals_NNS prior_RB to_TO the_DT start_NN of_IN therapy_NN was_VBD obtained_VBN for_IN all_DT isolates_NNS ,_, with_IN an_DT average_JJ bacterial_JJ density_NN of_IN 6.09_CD +-_NN 0.23_CD log10_NN CFU_NP per_IN thigh_NN ._SENT These_DT data_NNS support_VBP the_DT accuracy_NN of_IN inoculum_NN preparation_NN and_CC the_DT consistency_NN of_IN the_DT inoculation_NN procedure_NN ._SENT Figure_NN displays_NNS the_DT growth_NN of_IN each_DT organism_NN in_IN control_NN animals_NNS over_IN the_DT 24-h_JJ postinfection_NN period_NN ._SENT Average_JJ bacterial_JJ growth_NN in_IN untreated_JJ control_NN animals_NNS over_IN 24_CD h_NN was_VBD 2.1_CD +-_NN 0.55_CD log10_NN CFU_NP per_IN thigh_NN ,_, with_IN a_DT range_NN from_IN 0.9_CD to_TO 2.9_CD log10_NN CFU_NP per_IN thigh_NN ._SENT The_DT mean_JJ changes_NNS in_IN bacterial_JJ density_NN at_IN the_DT conclusion_NN of_IN 24_CD h_NN of_IN therapy_NN with_IN 50_CD mg_NN of_IN ertapenem/kg_NN q6h_NN are_VBP presented_VBN in_IN Fig._NN ._SENT The_DT magnitude_NN of_IN killing_VBG ranged_VBN from_IN 0.22_CD to_TO 4.4_CD log10_NN CFU_NP per_IN thigh_NN over_IN 24_CD h_NN ,_, and_CC the_DT extent_NN of_IN microbial_JJ eradication_NN appeared_VBD to_TO be_VB related_VBN to_TO the_DT MIC_NN for_IN the_DT pneumococcal_JJ isolate_NN ._SENT Substantial_JJ bactericidal_JJ activities_NNS were_VBD observed_VBN against_IN isolates_NNS for_IN which_WDT MICs_NP were_VBD <=2_mg/liter, MICfree_JJ for_IN ertapenem_NN after_IN 24_CD h_NN of_IN therapy_NN (_( P_NN <_0.05). MICfree_NP and_CC log10_NP CFU_NP was_VBD further_RBR described_VBN with_IN a_DT sigmoid_JJ Emax_NP model_NN ._SENT As_IN shown_VBN in_IN Fig._NN ,_, maximal_JJ bacterial_JJ killing_NN activity_NN appears_VBZ to_TO be_VB reached_VBN once_IN the_DT T>MICfree_NP exceeds_VBZ 30_CD %_NN ._SENT A_DT comparison_NN between_IN the_DT bactericidal_JJ activities_NNS of_IN ertapenem_NN in_IN neutropenic_JJ ICR_NP mice_NNS and_CC nonneutropenic_JJ CBA/J_NP mice_NNS was_VBD undertaken_VBN ._SENT Excellent_JJ recovery_NN of_IN bacteria_NNS was_VBD observed_VBN for_IN both_DT ICR_NP and_CC CBA/J_NP mice_NNS at_IN 2_CD h_NN after_IN bacterial_JJ inoculation_NN ,_, which_WDT is_VBZ consistent_JJ with_IN previous_JJ data_NNS ._SENT However_RB ,_, levels_NNS of_IN bacterial_JJ growth_NN in_IN untreated_JJ control_NN ICR_NN mice_NNS and_CC untreated_JJ control_NN CBA/J_NP mice_NNS were_VBD significantly_RB different_JJ (_( P_NN <_SYM 0.05_CD )_) after_IN 24_CD h_NN of_IN inoculation_NN ._SENT Organisms_NNS grew_VBD approximately_RB 2.5_CD log10_NN CFU_NP per_IN thigh_NN over_IN 24_CD h_NN in_IN untreated_JJ ICR_NP mice_NNS ,_, while_IN an_DT average_JJ reduction_NN in_IN bacterial_JJ density_NN of_IN 1.1_CD log10_NN CFU_NP per_IN thigh_NN was_VBD observed_VBN for_IN untreated_JJ CBA/J_NP mice_NNS ._SENT Furthermore_RB ,_, significantly_RB different_JJ bactericidal_JJ effects_NNS were_VBD observed_VBN for_IN ertapenem-treated_JJ ICR_NP versus_CC CBA/J_NP mice_NNS ._SENT As_IN shown_VBN in_IN Fig._NN ,_, the_DT bactericidal_JJ activity_NN observed_VBN in_IN CBA/J_NP mice_NNS was_VBD considerably_RB enhanced_VBN over_IN that_DT in_IN ICR_NP mice_NNS (_( P_NN <_0.05). MICfree_NP ._SENT FIG._NN 1_CD ._SENT |_SYM Population_NP predicted_VBD concentrations_NNS versus_IN concentrations_NNS observed_VBN by_IN NONMEM_NP analysis_NN ._SENT Population_NN predicted_VBD concentrations_NNS versus_IN concentrations_NNS observed_VBN by_IN NONMEM_NP analysis_NN ._SENT FIG._NN 2_CD ._SENT |_SYM Goodness_NP of_IN fit_NN between_IN the_DT NONMEM_NP simulated_JJ ertapenem_NN concentration-time_JJ profile_NN after_IN 50-mg/kg_NN dosing_VBG and_CC the_DT mean_JJ observed_JJ serum_NN ertapenem_NN concentration-versus-time_JJ profile_NN in_IN the_DT murine_JJ thigh_NN infection_NN model_NN ._SENT Goodness_NN of_IN fit_NN between_IN the_DT NONMEM_NP simulated_JJ ertapenem_NN concentration-time_JJ profile_NN after_IN 50-mg/kg_NN dosing_VBG and_CC the_DT mean_JJ observed_JJ serum_NN ertapenem_NN concentration-versus-time_JJ profile_NN in_IN the_DT murine_JJ thigh_NN infection_NN model_NN ._SENT FIG._NN 3_CD ._SENT |_SYM Densities_NP of_IN S._NP pneumoniae_NP Densities_NP of_IN S._NP pneumoniae_NNS in_IN the_DT thighs_NNS of_IN infected_JJ animals_NNS at_IN the_DT start_NN of_IN therapy_NN ._SENT Each_DT value_NN represents_VBZ 1_CD of_IN 16_CD isolates_NNS and_CC is_VBZ the_DT mean_JJ +-_NN standard_JJ deviation_NN for_IN 8_CD thighs_NNS ._SENT FIG._NN 4_CD ._SENT |_SYM Growth_NN in_IN density_NN of_IN S._NP pneumoniae_NNS Growth_NN in_IN density_NN of_IN S._NP pneumoniae_NNS in_IN the_DT thighs_NNS of_IN infected_JJ control_NN animals_NNS over_IN 24_CD h._NNS Each_DT value_NN represents_VBZ 1_CD of_IN 16_CD isolates_NNS and_CC is_VBZ the_DT mean_JJ +-_NN standard_JJ deviation_NN for_IN 8_CD thighs_NNS ._SENT FIG._NN 5_CD ._SENT |_SYM Changes_NP in_IN density_NN of_IN S._NP pneumoniae_NP Changes_NP in_IN density_NN of_IN S._NP pneumoniae_NNS in_IN the_DT thighs_NNS of_IN infected_JJ animals_NNS after_IN 24_CD h_NN of_IN ertapenem_NN therapy_NN ._SENT Each_DT value_NN represents_VBZ 1_CD of_IN 16_CD isolates_NNS and_CC is_VBZ the_DT mean_JJ +-_NN standard_JJ deviation_NN for_IN 8_CD thighs_NNS ._SENT FIG._NN 6_CD ._SENT |_SYM Sigmoid_NP Emax_NP evaluation_NN of_IN the_DT correlation_NN between_IN T>MICfree_NP and_CC the_DT bactericidal_JJ activity_NN of_IN ertapenem_NN ._SENT Sigmoid_JJ Emax_NP evaluation_NN of_IN the_DT correlation_NN between_IN T>MICfree_NP and_CC the_DT bactericidal_JJ activity_NN of_IN ertapenem_NN ._SENT r2_NN =_SYM 0.88_CD ._SENT FIG._NN 7_CD ._SENT |_SYM Growth_NN in_IN density_NN of_IN S._NP pneumoniae_NNS Growth_NN in_IN density_NN of_IN S._NP pneumoniae_NP (_( SP-129_NP )_) in_IN the_DT thighs_NNS of_IN infected_JJ immunocompromised_NNS (_( ICR_NP )_) and_CC immunocompetent_JJ (_( CBA/J_NP )_) control_NN animals_NNS over_IN 24_CD h._JJ Values_NNS are_VBP means_VBZ +-_JJ standard_JJ deviations_NNS for_IN 8_CD thighs_NNS ._SENT FIG._NN 8_CD ._SENT |_SYM Changes_NP in_IN density_NN of_IN S._NP pneumoniae_NP Changes_NP in_IN density_NN of_IN S._NP pneumoniae_NP (_( SP-129_NP )_) in_IN the_DT thighs_NNS of_IN infected_JJ immunocompromised_NNS (_( ICR_NP )_) and_CC immunocompetent_JJ (_( CBA/J_NP )_) animals_NNS after_IN 24_CD h_NN of_IN ertapenem_NN therapy_NN ._SENT Values_NNS are_VBP means_VBZ +-_JJ standard_JJ deviations_NNS for_IN 8_CD thighs_NNS ._SENT FIG._NN 9_CD ._SENT |_SYM Percentage_NN of_IN survival_NN of_IN pneumococcus-infected_JJ animals_NNS after_IN 4_CD days_NNS of_IN ertapenem_NN treatment_NN and_CC 3_CD days_NNS posttreatment_NN (_( n_NN =_SYM 15_CD )_) ._SENT Percentage_NN of_IN survival_NN of_IN pneumococcus-infected_JJ animals_NNS after_IN 4_CD days_NNS of_IN ertapenem_NN treatment_NN and_CC 3_CD days_NNS posttreatment_NN (_( n_NN =_SYM 15_CD )_) ._SENT Each_DT set_NN of_IN bars_NNS represents_VBZ one_CD S._NP pneumoniae_NNS isolate_VBP ._SENT TABLE_NN 1_CD |_SYM MICs_NN of_IN ertapenem_NN for_IN the_DT S._NP pneumoniae_NN test_NN isolates_VBZ TABLE_NP 2_CD |_SYM Population_NN pharmacokinetic_JJ parameter_NN estimates_NNS for_IN ertapenem_NN in_IN mice_NNS infected_VBN in_IN the_DT thigh_NN with_IN S._NP pneumoniae_NP S._NP pneumoniae_NP remains_VBZ one_CD of_IN the_DT leading_VBG causes_NNS of_IN community-acquired_JJ bacterial_JJ infections_NNS ,_, and_CC severe_JJ S._NP pneumoniae_NNS infections_NNS such_JJ as_IN pneumonia_NN and_CC meningitis_NN have_VBP significant_JJ morbidity_NN and_CC mortality_NN rates_NNS ._SENT In_IN the_DT present_JJ study_NN ,_, we_PP evaluated_VBD the_DT pharmacodynamic_JJ profile_NN of_IN ertapenem_NN against_IN 16_CD clinical_JJ isolates_NNS of_IN S._NP pneumoniae_NNS with_IN a_DT wide_JJ range_NN of_IN sensitivities_NNS by_IN using_VBG the_DT neutropenic_JJ murine_JJ model_NN of_IN thigh_NN infection_NN ._SENT It_PP has_VBZ been_VBN shown_VBN that_IN the_DT most_RBS important_JJ pharmacokinetic/pharmacodynamic_JJ parameter_NN for_IN prediction_NN of_IN the_DT antimicrobial_JJ effect_NN of_IN ertapenem_NN is_VBZ T>MIC_JJ (_( M._NP L._NP Van_NP Ogtrop_NP ,_, D._NP Andes_NP ,_, and_CC W._NP A._NP Craig_NP ,_, Abstr_NP ._SENT 39th_JJ Intersci_NP ._SENT Conf_NP ._SENT Antimicrob_NN ._SENT Agents_NPS Chemother_NP ._SENT ,_, abstr_NN ._SENT 999_CD ,_, 1999_CD )_) ._SENT In_IN addition_NN ,_, ertapenem_NN has_VBZ been_VBN reported_VBN as_IN a_DT highly_RB protein-bound_JJ drug_NN ,_, which_WDT is_VBZ in_IN accordance_NN with_IN our_PP$ observation_NN (_( 95_CD %_NN bound_NN ;_: Merck_NP &_CC Co._NP ,_, Inc._NP ,_, product_NN package_NN insert_NN ,_, 2001_CD )_) ._SENT Therefore_RB ,_, the_DT dosing_VBG regimen_NN employed_VBN in_IN this_DT study_NN was_VBD selected_VBN based_VBN on_IN the_DT drug_NN exposure_NN found_VBN in_IN humans_NNS following_VBG 1-g_JJ q24h_NN dosing_VBG ,_, in_IN which_WDT the_DT T>MICfree_NP is_VBZ approximately_RB 20_CD %_NN ._SENT In_IN the_DT present_JJ study_NN ,_, the_DT serum_NN pharmacokinetic_JJ profile_NN produced_VBN by_IN the_DT 50-mg/kg_JJ q6h_NN dosing_VBG regimen_NN in_IN our_PP$ model_NN was_VBD quite_RB similar_JJ to_TO the_DT target_NN exposure_NN in_IN humans_NNS ._SENT Over_IN the_DT course_NN of_IN the_DT study_NN ,_, excellent_JJ recovery_NN of_IN bacteria_NNS from_IN infected_JJ thighs_NNS was_VBD noted_VBN for_IN all_PDT the_DT isolates_NNS prior_RB to_TO the_DT initiation_NN of_IN therapy_NN ._SENT However_RB ,_, the_DT growth_NN of_IN organisms_NNS in_IN untreated_JJ control_NN animals_NNS over_IN the_DT 24-h_JJ treatment_NN period_NN was_VBD quite_RB variable_JJ ,_, revealing_VBG the_DT inherent_JJ variability_NN of_IN in_IN vivo_JJ growth_NN of_IN S._NP pneumoniae_NNS ,_, which_WDT is_VBZ consistent_JJ with_IN previous_JJ findings_NNS ._SENT Use_NN of_IN the_DT simulated_JJ exposure_NN with_IN a_DT number_NN of_IN S._NP pneumoniae_NNS strains_NNS for_IN which_WDT MICs_NP were_VBD varied_VBN yielded_VBD a_DT wide_JJ range_NN of_IN levels_NNS of_IN bacterial_JJ killing_NN over_IN the_DT 24_CD h_NN of_IN therapy_NN ._SENT The_DT extent_NN of_IN bacterial_JJ killing_NN appears_VBZ to_TO be_VB related_VBN to_TO the_DT MIC_NN of_IN ertapenem_NN for_IN the_DT pneumococcal_JJ isolate_NN ._SENT Substantial_JJ bactericidal_JJ activities_NNS were_VBD consistently_RB observed_VBN against_IN isolates_NNS for_IN which_WDT MICs_NP were_VBD <=2_mg/liter. MICfree_NP was_VBD closely_RB correlated_VBN with_IN efficacy_NN ,_, and_CC the_DT relationship_NN between_IN these_DT two_CD parameters_NNS can_MD be_VB adequately_RB described_VBN with_IN the_DT sigmoid_JJ Emax_NP model_NN ._SENT In_IN addition_NN ,_, as_RB shown_VBN in_IN Fig._NN ,_, the_DT T>MICfree_NP required_VBN for_IN a_DT static_JJ effect_NN is_VBZ approximately_RB 6_CD %_NN ,_, which_WDT is_VBZ in_IN agreement_NN with_IN previous_JJ observations_NNS (_( M._NP L._NP Van_NP Ogtrop_NP ,_, D._NP Andes_NP ,_, and_CC W._NP A._NP Craig_NP ,_, Abstr_NP ._SENT 38th_JJ Intersci_NP ._SENT Conf_NP ._SENT Antimicrob_NN ._SENT Agents_NPS Chemother_NP ._SENT ,_, abstr_NP ._SENT F-48_NP ,_, 1998_CD )_) ._SENT The_DT magnitude_NN of_IN the_DT pharmacokinetic/pharmacodynamic_JJ parameter_NN required_VBN for_IN a_DT static_JJ effect_NN is_VBZ much_RB less_JJR than_IN that_DT observed_VBN with_IN penicillin_NN and_CC cephalosporins_NNS ._SENT Moreover_RB ,_, we_PP compared_VBD the_DT bacterial-density_NN determinations_NNS for_IN the_DT immunocompromised_JJ (_( ICR_NP mice_NNS )_) and_CC the_DT immunocompetent_JJ (_( CBA/J_NP mice_NNS )_) host_NN with_IN the_DT same_JJ pneumococcal_JJ strain_NN ._SENT A_DT substantial_JJ enhancement_NN in_IN bactericidal_JJ activity_NN was_VBD observed_VBN for_IN the_DT CBA/J_NP mice_NNS ;_: this_DT is_VBZ attributed_VBN to_TO the_DT contribution_NN of_IN the_DT host_NN defenses_NNS in_IN the_DT immunocompetent_JJ species_NN ._SENT This_DT is_VBZ in_IN accordance_NN with_IN a_DT previous_JJ observation_NN ,_, which_WDT also_RB demonstrates_VBZ the_DT host_NN immunocompetency_NN effect_NN on_IN efficacy_NN ._SENT In_IN summary_NN ,_, ertapenem_NN demonstrated_VBD substantial_JJ bactericidal_JJ activity_NN against_IN S._NP pneumoniae_NNS in_IN the_DT murine_JJ thigh_NN infection_NN model_NN ._SENT The_DT relationship_NN between_IN T>MIC_JJ and_CC bactericidal_JJ activity_NN can_MD be_VB characterized_VBN with_IN the_DT sigmoid_JJ Emax_NP model_NN ._SENT In_IN the_DT context_NN of_IN the_DT isolates_NNS and_CC dosing_VBG regimen_NN studied_VBD ,_, ertapenem_NN therapy_NN protected_VBD animals_NNS from_IN death_NN ._SENT Enhanced_VBN bactericidal_JJ activities_NNS were_VBD observed_VBN in_IN the_DT immunocompetent_JJ animals_NNS ._SENT Based_VBN on_IN these_DT data_NNS and_CC the_DT consideration_NN that_IN the_DT presence_NN of_IN neutrophils_NNS would_MD be_VB expected_VBN to_TO further_RBR enhance_VB the_DT activity_NN of_IN ertapenem_NN ,_, the_DT proposed_VBN susceptibility_NN breakpoint_NN for_IN ertapenem_NN would_MD be_VB 2_CD mg/liter_NN ._SENT 